ArticleThe Journal of infectious diseases2017
Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Impediments to Progress Toward Polio Eradication During 2014-2024: Effectively Addressing the Current Challenges.Vaccines · 2025Review
- Immune and Safety Analysis ofViruses · 2025Article
- Reflections on 50 years of immunisation programmes in the WHO African region: an impetus to build on the progress and address the unfinished immunisation business.BMJ global health · 2025Article
- Updates on the polio surveillance action plan's key performance indicators: East and Southern African countries (January 2022 to December 2023).The Pan African medical journal · 2025Article
- A highly immunogenic UVC inactivated Sabin based polio vaccine.NPJ vaccines · 2024Article
- Temporal and spatial distribution trends of polio vaccine coverage in less than one-year old children in Brazil, 2011-2021.BMC public health · 2023Article
- Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China.The Lancet regional health. Western Pacific · 2023Article
- Descriptive epidemiology of poliomyelitis cases due to wild poliovirus type 1 and wild poliovirus type 3 in Nigeria, 2000-2020.The Pan African medical journal · 2023Article
- The Long and Winding Road to Eradicate Vaccine-Related Polioviruses.The Journal of infectious diseases · 2021Article
- The experiences of using polio outbreak simulation exercises to strengthen national outbreaks preparedness and response plans in sub-Saharan Africa.The Pan African medical journal · 2020Article
- Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel?The Journal of infectious diseases · 2019Article
- Prevalence of poliovirus vaccine strains in randomized stool samples from 2010 to 2018: encompassing transition from the trivalent to bivalent oral poliovirus vaccine.Virusdisease · 2019Article
- Twitter Conversations and English News Media Reports on Poliomyelitis in Five Different Countries, January 2014 to April 2015.The Permanente journal · 2019Article
- Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.PloS one · 2019Article
- Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.Journal of virology · 2018Article
- The contribution of the polio eradication initiative on the operations and outcomes of non-polio public health programs: a survey of programs in the African region.The Pan African medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Global Commission for the Certification of the Eradication of Poliomyelitis certified the eradication of type 2 poliovirus in September 2015, making type 2 poliovirus the first human pathogen to be eradicated since smallpox. The eradication of type 2 poliovirus, the absence of detection of type 3 poliovirus worldwide since November 2012, and cornering type 1 poliovirus to only a few geographic areas of 3 countries has enabled implementation of the endgame of polio eradication which calls for a phased withdrawal of oral polio vaccine beginning with the type 2 component, introduction of inactivated poliovirus vaccine, strengthening of routine immunization in countries with extensive polio resources, and initiating activities to transition polio resources, program experience, and lessons learned to other global health initiatives. This supplement focuses on efforts by global partners to successfully launch polio endgame activities to permanently secure and sustain the enormous gains of polio eradication forever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.